Le Centre de recherche Douglas
Published on Le Centre de recherche Douglas (https://douglas.research.mcgill.ca)

Accueil > Effectiveness and acceptability of accelerated repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depressive disorder: an open label trial.

Effectiveness and acceptability of accelerated repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depressive disorder: an open label trial.

TitleEffectiveness and acceptability of accelerated repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depressive disorder: an open label trial.
Publication TypeJournal Article
Year of Publication2015
AuthorsMcGirr A [1], Van den Eynde F [2], Tovar-Perdomo S [3], Fleck MPA [4], Berlim M [5]
JournalJ Affect Disord
Volume173
Pagination216-20
Date Published2015 Mar 1
ISSN1573-2517
KeywordsAdult [6], Antidepressive Agents [7], Combined Modality Therapy [8], Depressive Disorder, Major [9], Depressive Disorder, Treatment-Resistant [10], Female [11], Humans [12], Male [13], Middle Aged [14], Quality of Life [15], Transcranial Magnetic Stimulation [16], Treatment Outcome [17]
Abstract

BACKGROUND: Major depressive disorder (MDD) is a significant cause of worldwide disability and treatment resistance is common. High-frequency repetitive transcranial magnetic stimulation (HF-rTMS) has emerged as a treatment for MDD, and while efficacious, the daily commitment for typical 4-6 weeks of treatment poses a significant challenge. We aimed to determine the effectiveness and acceptability of an accelerated rTMS protocol for MDD.METHODS: In this naturalistic trial, 27 patients with moderate to severe chronic and treatment-resistant MDD were treated with twice-daily HF-rTMS (10 Hz) applied over the left dorsolateral prefrontal cortex for 2 consecutive weeks (60,000 pulses). The primary outcomes were rates of clinical remission and response (16-item Quick Inventory of Depressive Symptomatology post-treatment score ≤ 6, and ≥ 50% reduction, respectively). Secondary outcomes were self-reported anxious symptoms, depressive symptoms and quality of life, and dropout rates as a proxy for acceptability.RESULTS: Ten (37.0%) patients met criteria for clinical remission and 15 (55.6%) were classified as responders, with comparable outcomes for both moderate and severe MDD. Clinician-rated improvements in depressive symptoms were paralleled in self-reported depressive and anxious symptoms, as well as quality of life. No patient discontinued treatment.LIMITATIONS: This study is limited by short treatment duration that might be lengthened with corresponding improvements in effectiveness, limited duration of follow-up, small sample size, and an open-label design requiring randomized controlled replication.CONCLUSION: An accelerated protocol involving twice-daily sessions of HF-rTMS over the left DLPFC for 2 weeks was effective in treatment-resistant MDD, and had excellent acceptability. Additional research is required to optimize accelerated rTMS treatment protocols and determine efficacy using sham-controlled trials.

DOI10.1016/j.jad.2014.10.068 [18]
Alternate JournalJ Affect Disord
PubMed ID25462419 [19]

Source URL: https://douglas.research.mcgill.ca/fr/effectiveness-and-acceptability-accelerated-repetitive-transcranial-magnetic-stimulation-rtms

Links
[1] https://douglas.research.mcgill.ca/fr/publications?f%5Bauthor%5D=4061
[2] https://douglas.research.mcgill.ca/fr/publications?f%5Bauthor%5D=4062
[3] https://douglas.research.mcgill.ca/fr/publications?f%5Bauthor%5D=4866
[4] https://douglas.research.mcgill.ca/fr/publications?f%5Bauthor%5D=4064
[5] https://douglas.research.mcgill.ca/fr/publications?f%5Bauthor%5D=5775
[6] https://douglas.research.mcgill.ca/fr/publications?f%5Bkeyword%5D=2787
[7] https://douglas.research.mcgill.ca/fr/publications?f%5Bkeyword%5D=3155
[8] https://douglas.research.mcgill.ca/fr/publications?f%5Bkeyword%5D=3677
[9] https://douglas.research.mcgill.ca/fr/publications?f%5Bkeyword%5D=2828
[10] https://douglas.research.mcgill.ca/fr/publications?f%5Bkeyword%5D=3383
[11] https://douglas.research.mcgill.ca/fr/publications?f%5Bkeyword%5D=2779
[12] https://douglas.research.mcgill.ca/fr/publications?f%5Bkeyword%5D=2782
[13] https://douglas.research.mcgill.ca/fr/publications?f%5Bkeyword%5D=2783
[14] https://douglas.research.mcgill.ca/fr/publications?f%5Bkeyword%5D=2833
[15] https://douglas.research.mcgill.ca/fr/publications?f%5Bkeyword%5D=2988
[16] https://douglas.research.mcgill.ca/fr/publications?f%5Bkeyword%5D=2870
[17] https://douglas.research.mcgill.ca/fr/publications?f%5Bkeyword%5D=2871
[18] http://dx.doi.org/10.1016/j.jad.2014.10.068
[19] https://www.ncbi.nlm.nih.gov/pubmed/25462419?dopt=Abstract